Related Experiment Video

Updated: Jul 15, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis

Amar A Sethi1, Marcelo Amar, Robert D Shamburek

  • 1National Institutes of Health, Lipoprotein Metabolism Section, Vascular Medicine Branch, National Heart, Lung and Blood Institute, Bldg 10, Room 7N-115, 10 Center Drive, Bethesda, MD 20892-1508, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|April 6, 2007
PubMed

Insights

Raising HDL cholesterol offers a promising new strategy for preventing coronary heart disease (CHD). Apolipoprotein AI mimetic peptides are being explored as novel therapeutic agents for acute HDL therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Current therapies targeting low-density lipoprotein (LDL) are insufficient for fully preventing coronary heart disease (CHD).
  • There is a growing need for therapeutic agents that increase high-density lipoprotein (HDL) levels to augment existing treatments.
  • Recent advances in understanding HDL metabolism have identified new protein targets for drug development.

Purpose of the Study:

  • To review the potential of apolipoprotein AI mimetic peptides as therapeutic agents.
  • To explore the strategy of acute HDL therapy for cardiovascular disease prevention.
  • To highlight novel drug targets emerging from HDL metabolism research.

Main Methods:

  • Review of current scientific literature on HDL metabolism and therapeutic strategies.
  • Focus on apolipoprotein AI mimetic peptides and their mechanisms of action.
  • Analysis of the concept and potential application of acute HDL therapy.

Main Results:

  • Apolipoprotein AI mimetic peptides show promise as a new class of drugs.
  • Acute HDL therapy represents a novel treatment strategy for CHD.
  • Understanding HDL metabolism provides new avenues for pharmaceutical intervention.

Conclusions:

  • Therapeutic agents for raising HDL are a valuable addition to CHD prevention.
  • Apolipoprotein AI mimetic peptides are key candidates for acute HDL therapy.
  • Targeting HDL metabolism offers significant potential for future cardiovascular treatments.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...